Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen (TAPA)-Pulsed Dendritic Cell (DC) Therapy and Low Dose GM-CSF, as Consolidation Therapy in Patients With Metastatic Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs TAPA-pulsed DC vaccine (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kiromic
- 01 Aug 2017 Planned End Date changed from 1 Sep 2017 to 31 Jan 2019.
- 01 Aug 2017 Planned primary completion date changed from 1 May 2017 to 31 Oct 2018.
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.